Addition of abiraterone to ADT/docetaxel does not increase bone loss

Addition of abiraterone to ADT/docetaxel does not increase bone loss

Presented By

Dr Guilhem Roubaud, Institut Bergonié, France

Trial

Phase 3, PEACE-1

Conference

ASCO GU 2022

8 April, 2022 11:21

DCF outperforms standard-of-care for locally advanced oesophageal cancer

Presented By

Dr Ken Kato, National Cancer Center Hospital, Japan

Trial

Phase 3, JCOG1109, NExT

Conference

ASCO GI 2022

21 March, 2022 11:13

ASCO GI 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ASCO GI 2022

8 February, 2022 12:37

Concurrent taxane plus anthracycline most beneficial in reducing risk of breast cancer

Presented By

Dr Jeremy Braybrooke, University Hospitals Bristol NHS Foundation Trust, UK

Conference

SABCS 2021

31 January, 2022 16:44

Both men with high-risk non-metastatic prostate cancer and men with metastatic prostate cancer benefit from intensified hormone treatment

Trial

Phase 3, PEACE-1, STAMPEDE, ARCHES

Conference

ESMO 2021

19 November, 2021 09:27

Radiographic PFS benefit of adding abiraterone to ADT and docetaxel in mCSPC

Presented By

Prof. Karim Fizazi, University of Paris-Saclay, Villejuif, France

Trial

Phase 3, PEACE-1

Conference

EAU 2021

31 August, 2021 12:15

177Lu-PSMA-617: A new class of effective therapy

Presented By

Prof. Johann de Bono; Prof. Michael Hofman

Trial

VISION, TheraP

Conference

EAU 2021

31 August, 2021 12:15

Perioperative chemotherapy and neoadjuvant multimodality therapy appear equally effective

Presented By

Prof. John Reynolds, Trinity St James Cancer Institute, Ireland

Trial

Phase 3, Neo-AEGIS

Conference

ASCO 2021

12 August, 2021 13:18

Lu177 as a promising new therapy for metastatic prostate cancer

Presented By

Dr Michael Hofman, Peter MacCallum Cancer Centre, Australia

Trial

Phase 2, TheraP

Conference

ASCO GU 2021

24 March, 2021 14:49

Neoadjuvant chemotherapy does not increase perioperative complications in thoracic oesophageal cancer

Presented By

Prof. Kazuo Koyanagi, National Cancer Center, Japan

Trial

Phase 3, JCOG 1109

Conference

ASCO GI 2021

12 March, 2021 11:42

Adding docetaxel to adjuvant S-1 reduces gastric cancer relapse

Presented By

Prof. Kazuhiro Yoshida, Gifu University, Japan

Trial

Phase 2, JACCRO GC-07

Conference

ASCO GI 2021

12 March, 2021 11:38

Docetaxel + hormonal therapy: improved prostate cancer PFS

Presented By

Dr Andreas Josefsson , Sahlgrenska University Hospital, Sweden

Trial

Phase 3, SPCG-14

Conference

EAU 2020

21 August, 2020 14:34

Understanding MIBC biology for novel treatment options

Presented By

Prof. Yohann Loriot, Université Paris-Saclay, France

Trial

BLC2001; THOR; EV-301; EV-302; TROPHY-U-01; RANGE

Conference

EAU 2020

20 August, 2020 12:36

Sensory peripheral neuropathy after taxane treatment is not uncommon

Conference

10:04:40pm> hello nurse from conference

13 February, 2020 21:50

No added benefit for doxorubicin + docetaxel vs doxorubicin + cyclophosphamide

Conference

SABCS 2019

13 February, 2020 12:51

Five-fold increase of OS at 5 years with nivolumab vs docetaxel

Presented By

Prof. Scott Gettinger, Yale Cancer Center, USA

Trial

CheckMate 017, CheckMate 057

Conference

WCLC 2019

8 November, 2019 23:00

Avelumab vs docetaxel for previously treated advanced non-small-cell lung cancer

Trial

Phase 3, JAVELIN Lung 200

Conference

WCLC 2018

21 November, 2018 22:46

Medical Conferences

Tag: docetaxel